Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK4 Inhibitor
Emavusertib hydrochloride is an orally active inhibitor targeting IRAK4, with an IC50 of 57 nM, and FLT3. This compound effectively inhibits NF-κB and MyD88 signaling pathways, resulting in decreased production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, as it promotes apoptosis in cancer cells and demonstrates antitumor efficacy in mouse model studies. -
Immunomodulator
Laquinimod sodium is a potent immunomodulator targeting neuroinflammation and neurodegeneration within the central nervous system. This orally available carboxamide derivative effectively reduces astrocytic NF-κB activation, offering protection against Cuprizone-induced demyelination. Laquinimod sodium is applicable in research focused on relapsing-remitting and chronic progressive forms of multiple sclerosis, as well as in studies of various neurodegenerative diseases. -
Cereblon Modulator
Avadomide hydrochloride is an oral cereblon modulator that targets cereblon E3 ligase activity. By inhibiting the NF-κB signaling pathway and arresting the cell cycle at the G1 phase, it effectively induces apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. This compound demonstrates significant antitumor and immunomodulatory properties, making it a valuable reagent for cancer research applications. -
Apoptosis Inducer
Apoptosis Inducer 46 targets apoptotic pathways to induce cell death selectively in metastatic triple-negative breast cancer (TNBC) cells. It demonstrates potent growth inhibitory effects, specifically causing G2/M phase cell cycle arrest and promoting apoptotic cell death in MDA-MB-231 cells. Additionally, Apoptosis Inducer 46 inhibits NF-κB nuclear translocation, highlighting its potential for research applications in the study of TNBC. -
Antioxidant
Astaxanthin is a potent antioxidant primarily targeting NF-κB, leading to the down-regulation of VEGF in blood glucose regulation. This carotenoid exhibits significant anti-cancer properties by inhibiting cell proliferation, enhancing apoptosis, and preventing migration and invasion through PPARγ activation and STAT3 expression reduction. Additionally, astaxanthin demonstrates neuroprotective and anti-inflammatory activities, making it applicable in various research fields, including cancer, diabetic retinopathy, and cardiovascular disease, as well as in the enhancement of animal feed coloration. -
Short-chain Fatty Acid
Sodium propionate is a short-chain fatty acid with multiple biological activities, primarily functioning as an oral bioactive compound. It enhances PPAR-γ activity while inhibiting NF-κB activation, leading to reduced COX-2 expression and nitric oxide production. Additionally, sodium propionate has demonstrated the ability to induce apoptosis and autophagy, exhibit anticancer effects against glioblastoma, and provide neuroprotective, antioxidant, and anti-inflammatory properties. This compound is suitable for research applications in areas such as spinal cord injury and Alzheimer's disease. -
TLR7/8 Antagonist
Afimetoran is a selective and highly bioavailable antagonist of Toll-like receptors 7 and 8 (TLR7/8). It effectively inhibits TLR7/8-mediated activation of the NF-κB signaling pathway and can reverse TLR7-induced resistance to steroid-driven apoptosis in plasmacytoid dendritic cells. This compound is particularly relevant for research into inflammation and autoimmune diseases, including systemic lupus erythematosus. -
Vascular Function Regulator
12-HETE is a significant metabolite of arachidonic acid produced via 12-lipoxygenase (12-LOX) catalysis, functioning as a vascular function regulator. It exhibits dose-dependent inhibition of cell apoptosis and promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway. Additionally, 12-HETE has been shown to possess both anti-thrombotic and pro-thrombotic effects, as well as neuromodulatory properties, making it valuable for research in vascular biology and related therapeutic areas. -
TRIP13 Inhibitor
DCZ0415 is a potent inhibitor of TRIP13, interfering with the nonhomologous end joining DNA repair mechanism and inhibiting NF-κB activity. This compound exhibits significant anti-myeloma activity in vitro, in vivo, and in primary cells obtained from drug-resistant myeloma patients, making it a valuable tool for research into therapeutic strategies against multiple myeloma. Its mechanism of action offers insights into the role of TRIP13 in cancer biology and the potential for targeted therapies. -
TLR2/4 Inhibitor
Robinin is a flavonoid that acts as an inhibitor of Toll-like receptors 2 and 4 (TLR2/4), modulating the TGF-β, TLR4/NF-κB, and TLR2-PI3k-AKT signaling pathways. This compound demonstrates significant anti-inflammatory and anti-tumor properties. Additionally, Robinin has been shown to enhance the anti-inflammatory effects of Methotrexate in experimental arthritis models and may mitigate cardiac toxicity induced by Doxorubicin. These attributes make Robinin a valuable reagent for research applications in inflammation and cancer therapy. -
Mucolytic Agent
Carbocisteine is an orally active mucolytic agent primarily targeting the modulation of mucous viscosity in respiratory conditions. It inhibits the phosphorylation of NF-κB p65 and ERK1/2, and further regulates the interplay between Nrf2/HO-1 and NF-κB pathways. Additionally, carbocisteine has demonstrated anti-apoptotic properties. This reagent is primarily utilized in research related to chronic obstructive pulmonary disease (COPD). -
ACE/IKK-β/PKC Inhibitor
Plantainoside D is a phenylethanoid glycoside that functions primarily as an inhibitor of IKK-β, with additional inhibitory effects on angiotensin-converting enzyme (ACE) and protein kinase C (PKC). It exhibits significant biological activities, including the reduction of glutamate release in the rat cerebral cortex, alleviating cell apoptosis through the inhibition of reactive oxygen species (ROS) and NF-κB activation. Additionally, Plantainoside D has been shown to improve outcomes in acute lung injury induced by sepsis via modulation of the Sirt3/NLRP3 signaling pathway. This compound is applicable in studies of neuroprotection, antioxidant activity, anti-inflammatory responses, and antihypertensive effects. -
TREM-1 Inhibitor
Nangibotide is a synthetic peptide that serves as a TREM-1 receptor inhibitor. By inhibiting NF-κB and NLRP3 inflammasome activation, Nangibotide effectively reduces the release of pro-inflammatory cytokines such as IL-1β and IL-8 and mitigates apoptosis. This reagent is valuable for research applications related to excessive inflammatory responses, including studies on myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure. Additionally, Nangibotide offers protective effects on tissues, such as the liver and lung, during inflammatory conditions. -
Bioactive Peptide
MOTS-c (human) is a bioactive peptide derived from mitochondria that modulates the AMPK/PGC-1α pathway, thereby enhancing insulin sensitivity. This peptide inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, which regulates the Nrf2/Keap1 antioxidant pathway and suppresses the NF-κB inflammatory pathway. MOTS-c promotes mitochondrial biogenesis and energy metabolism, resulting in improvements in glucose and lipid metabolism, anti-oxidative stress, and neuroprotection. It is applicable in research studying type 2 diabetes, traumatic brain injury, inflammatory diseases, and age-related metabolic disorders. -
Prolyl-hydroxylase Inhibitor
Ethyl 3,4-dihydroxybenzoate is a competitive inhibitor of prolyl hydroxylase, effectively penetrating the blood-brain barrier. By inhibiting the hydroxylation of hypoxia-inducible factor (HIF), it stabilizes HIF-1α, thereby activating downstream pathways that promote autophagy and apoptosis in tumor cells. Additionally, it modulates inflammatory responses, inhibits the NF-κB pathway, enhances vascular permeability, and supports osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate is beneficial for research applications focused on cancer therapeutics, cardiovascular protection, bone metabolism regulation, and high-altitude cerebral edema management. -
Keap1-Nrf2 Protein-Protein Inhibitor
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting an IC50 of 0.63 µM. This compound demonstrates significant anti-inflammatory and antioxidant properties by activating the Nrf2-dependent pathway and inhibiting the NF-κB-related inflammatory response. CPUY192018 is ideal for research applications focused on inflammation-related diseases and the modulation of oxidative stress. -
Anticancer/Antiparasitic Agents
Bruceine A, a natural quassinoid, primarily targets NF-κB and PFKFB4, demonstrating a Kd of 44 nM. This compound exhibits potent anticancer and antiparasitic activities, effectively inhibiting cancer cell migration and inducing apoptosis while also disrupting the cell cycle. Bruceine A is a valuable research tool for studying pancreatic cancer, breast cancer, and parasitic infections. -
Anti-inflammatory agent
Hederacoside C is a potent anti-inflammatory agent that targets the MAPK/NF-κB signaling pathway. It exerts its biological activity by inhibiting the activation of this pathway, resulting in a reduction of inflammation. In addition to its anti-inflammatory properties, Hederacoside C also demonstrates antibacterial activity, making it a valuable compound for research applications focused on inflammatory diseases and infections. - CMC2.24 (TRB-N0224) is an orally active tricarbonylmethane compound that exhibits antitumor activity in pancreatic cancer models by inhibiting Ras activation and downstream ERK1/2 signaling. It is also a potent inhibitor of zinc-dependent matrix metalloproteinases (MMPs), with IC₅₀ values ranging from 2.0 to 69 μM. Additionally, CMC2.24 has therapeutic potential in osteoarthritis, where it restores cartilage homeostasis and reduces chondrocyte apoptosis through modulation of the NF-κB/HIF-2α pathway.
-
TLR1/2 agonist
CU-T12-9 is a specific and potent agonist of the Toll-like receptor 1/2 (TLR1/2) heterodimer, with an EC₅₀ of 52.9 nM in the HEK-Blue hTLR2 SEAP assay. It selectively activates TLR1/2 without affecting TLR2/6 and stimulates both innate and adaptive immune responses. CU-T12-9 signals through the NF-κB pathway, leading to elevated expression of downstream effectors such as TNF-α, IL-10, and iNOS, making it a valuable tool for immunological and inflammatory research. -
DK/PI3K/BRD4 Inhibitor
SRX3177 is a potent triple inhibitor targeting CDK4/6, PI3K, and BRD4, with IC50 values of <2.5 nM for CDK4, 3.3 nM for CDK6, 79 nM for PI3Kα, 83 nM for PI3Kδ, 3.18 μM for PI3Kγ, and 33 nM and 89 nM for BRD4 BD1 and BD2, respectively. It exhibits broad cytotoxic activity against cancer cells while sparing normal epithelial cells, highlighting its potential as a targeted cancer therapeutic with reduced toxicity. -
RelB inhibitor
RS47 is a potent and specific inhibitor of the non-canonical NF-κB signaling pathway, acting by disrupting the binding of RelB to its target DNA with a Kd of 1.1 μM. It effectively inhibits the growth of colorectal cancer (CRC) cells and B lymphomas, making it a valuable research tool for studying and potentially targeting cancers driven by hyperactive non-canonical NF-κB signaling. -
SOD mimetic
MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger, classified as a manganic porphyrin complex with potent antioxidant properties. It exerts anti-inflammatory effects by upregulating BMPR-II expression and inhibiting NFκB signaling. MnTBAP chloride holds therapeutic potential for research into fibrotic responses in chronic kidney diseases (CKDs). -
Osteoclast formation inhibitor
ABD56 is a bioactive compound that inhibits osteoclast formation and induces osteoclast apoptosis. Its mechanism of action involves suppression of the NFκB and ERK signaling pathways, making it a promising candidate for research in bone metabolism and osteolytic diseases. -
PPAR agonist
Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases. -
Endoplasmic Reticulum Stress Inhibitor
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an inhibitor of endoplasmic reticulum (ER) stress that significantly downregulates pro-apoptotic molecules, including caspase-3 and caspase-12. Additionally, it suppresses ERK signaling, contributing to its cytoprotective and anti-apoptotic effects. -
NF-κB inhibitor
Asperulosidic Acid (ASPA) is a bioactive iridoid glycoside isolated from the herb Hedyotis diffusa Willd., exhibiting anti-tumor, antioxidant, and anti-inflammatory properties. Its anti-inflammatory effects are associated with the downregulation of proinflammatory cytokines such as TNF-α and IL-6, mediated through inhibition of the NF-κB and MAPK signaling pathways. -
Apoptosis activator
Sulforaphene, a natural compound isolated from radish seeds, exhibits an ED₅₀ of approximately 2 × 10⁻⁴ M against velvetleaf seedlings. It promotes apoptosis and inhibits migration in cancer cells by suppressing signaling pathways including EGFR, phosphorylated ERK1/2 (p-ERK1/2), and NF-κB. -
NF-κB/FAK/MAPK inhibitor
Keracyanin chloride is an orally active anthocyanin compound with potent antioxidant, anti-inflammatory, and hypoglycemic properties. It exerts its biological effects by inhibiting the NF-κB/FAK/MAPK signaling pathways, which are central to inflammation, cell adhesion, and metabolic regulation. -
Anticholinergic agent
Penehyclidine hydrochloride (also known as Penequinine hydrochloride) is a selective anticholinergic agent that acts as an antagonist of muscarinic M1 and M3 receptors. It exerts anti-inflammatory effects by modulating immune signaling in lung tissue, notably through activation of the NF-κB pathway and inhibition of pro-inflammatory cytokine release. In preclinical studies, Penehyclidine hydrochloride has been shown to alleviate pulmonary inflammation in rat models of chronic obstructive pulmonary disease (COPD), particularly under conditions of mechanical ventilation. These properties suggest its potential utility in managing respiratory inflammatory conditions and improving outcomes in mechanically ventilated patients with COPD. -
PPAR agonist
Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions. -
ACAT inhibitor
Enniatin B1 is a mycotoxin produced by Fusarium species, known for its diverse bioactivities. It functions as a moderate inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with an IC₅₀ of 73 μM in assays using rat liver microsomes, implicating a role in lipid metabolism modulation. Enniatin B1 is capable of crossing the blood-brain barrier, suggesting potential effects on central nervous system function. It also decreases the activation of ERK1/2 (p44/p42 MAPK) and moderately inhibits TNF-α-induced NF-κB activation, indicating anti-inflammatory and cell signaling modulatory properties. - Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue that exhibits potent anti-inflammatory activity. It exerts its effects by blocking mitogen-activated protein kinase (MAPK) signaling and inhibiting the nuclear translocation of the NF-κB subunit p65, thereby suppressing key inflammatory pathways. Additionally, compound 5a27 reduces neutrophil infiltration and the production of pro-inflammatory cytokines. In vivo, it significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI), highlighting its potential as a therapeutic candidate for inflammatory and respiratory disorders.
-
Endogenous Metabolite
Gamma-linolenic acid (γ-linolenic acid, GLA) is an orally active omega-6 unsaturated fatty acid with broad pharmacological activities. It exhibits anti-inflammatory effects by inhibiting the NF-κB signaling pathway and suppressing the phosphorylation of ERK1/2 and JNK, key mediators of inflammatory responses. GLA also induces apoptosis in cancer cells, contributing to its anticancer potential. Additionally, it possesses antioxidant properties and has been shown to improve memory function, suggesting neuroprotective benefits. These multifunctional effects position gamma-linolenic acid as a promising compound for research in inflammation, oncology, and neurological disorders. -
PDE4/NF-κB inhibitor
Sappanone A is an orally active homoisoflavone isolated from Caesalpinia sappan L., exhibiting notable anti-inflammatory and antioxidant properties. It functions as an inhibitor of phosphodiesterase 4 (PDE4) and NF-κB, key regulators of inflammatory signaling. Additionally, Sappanone A activates the Nrf2 pathway, leading to increased expression of the cytoprotective enzyme heme oxygenase-1 (HO-1). Sappanone A also inhibits RANKL-induced osteoclastogenesis, suggesting potential benefits in bone metabolism disorders. With its multifaceted bioactivity, Sappanone A holds significant promise for research in inflammation-related diseases, cardiovascular conditions, and bone health. -
NF-kB inhibitor
EF24 is a synthetic curcumin analogue and a potent NF-κB inhibitor with demonstrated oral bioavailability and strong antitumor activity. It exerts its anticancer effects, particularly in oral squamous cell carcinoma (OSCC), through deactivation of the MAPK/ERK signaling pathway. EF24 is effective against various cancer cell lines, with GI₅₀ values of 0.7 μM in melanoma and 0.8 μM in breast cancer cells. In MDA-MB-231 (breast cancer) and DU-145 (prostate cancer) cells, EF24 induces cell cycle arrest and apoptosis, accompanied by increased activation of caspase-3 and caspase-9. It also reduces the phosphorylation of MEK1 and ERK, further contributing to its pro-apoptotic and anti-proliferative effects. These properties make EF24 a promising compound for cancer therapy research. -
Microglial inhibitor
Inflachromene is a microglial inhibitor that exerts anti-inflammatory effects by directly binding to high mobility group box proteins HMGB1 and HMGB2. Through this interaction, it effectively downregulates the proinflammatory activities of HMGB proteins, leading to reduced microglial activation and neuronal damage. Inflachromene holds promise as a therapeutic candidate for the treatment of neuroinflammatory disorders, including neurodegenerative diseases and central nervous system injuries. - Gypenoside L is a bioactive saponin isolated from *Gynostemma pentaphyllum*, known for its diverse pharmacological properties. It induces cellular senescence by increasing senescence-associated β-galactosidase (SA-β-gal) activity and promoting the secretion of senescence-associated secretory phenotype (SASP) cytokines. Mechanistically, Gypenoside L activates the p38 and ERK MAPK pathways as well as the NF-κB signaling pathway to trigger senescence. In addition to its pro-senescent effects, Gypenoside L exhibits notable anti-tumor and anti-inflammatory activities, making it a promising compound for research in cancer biology and inflammation-related diseases.
-
NF-κB p65 Inhibitor
Licochalcone D is a naturally occurring flavonoid primarily found in the root of *Glycyrrhiza uralensis* (Chinese licorice). It functions as a potent and orally active inhibitor of the NF-κB p65 subunit, a key regulator of inflammation and cancer-related signaling pathways. Licochalcone D exhibits broad pharmacological properties, including antioxidant, anti-inflammatory, and anticancer activities, making it a promising candidate for research in inflammation-related diseases and oncology. -
Anti-inflammatory Agent
Berkeleyacetal C is a meroterpenoid compound that acts as an anti-inflammatory agent by inhibiting the NF-κB, ERK1/2, and IRF3 signaling pathways. It effectively reduces the expression of inducible nitric oxide synthase (iNOS) and subsequent nitric oxide production in macrophages. Additionally, Berkeleyacetal C suppresses the expression and secretion of key pro-inflammatory cytokines and chemokines, including TNF-α, IL-6, IL-1β, MIP-1α, and MCP-1, while also inhibiting neutrophil activation and reactive oxygen species (ROS) production. This compound is valuable for research into inflammatory disorders. -
TNF Receptor Inducer
SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer, primarily targeting NF-κB signaling. It effectively induces TNF-α production in isolated human peripheral blood mononuclear cells (PBMCs) at concentrations of 0.01 to 1 μM and exhibits an EC50 of 0.55 μM in cells expressing human TLR2. In vivo studies demonstrate that SMU127 (0.1 mg/animal) significantly reduces tumor volume in a 4T1 murine mammary carcinoma model, making it a valuable tool for research on immune response and cancer therapy. -
PDE Inhibitor
Theophylline sodium acetate functions as a potent phosphodiesterase (PDE) inhibitor, specifically targeting PDE3 to promote the relaxation of airway smooth muscle. It also acts as an adenosine receptor antagonist and histone deacetylase (HDAC) activator, contributing to its anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation to the nucleus. Additionally, Theophylline sodium acetate is known to induce apoptosis, making it a valuable reagent for research on asthma and chronic obstructive pulmonary disease (COPD). -
NF-κB Inhibitor
CAY10512 is a potent NF-κB inhibitor that effectively suppresses the upregulation of NF-κB-sensitive proinflammatory microRNAs, including miRNA-9, miRNA-125b, miRNA-146a, and miRNA-155, in cerebrospinal fluid and extracellular environments. This compound significantly reduces the release of pro-inflammatory cytokines such as TNF-α, MCP-1, IL-8, and IL-6. CAY10512 is valuable for research applications focused on neuroinflammation, islet transplantation, and the regulation of microRNA. -
TLR7 Agonist
SMU-L11-R is a selective TLR7 agonist that demonstrates an EC50 of 0.012 μM for human TLR7. This compound specifically activates TLR7, recruits MyD88, and initiates the MAPK/NF-κB signaling pathways, resulting in the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in both mouse and human peripheral blood mononuclear cells. Additionally, SMU-L11-R promotes M1-like macrophage polarization and exhibits synergistic anti-tumor effects in combination with PD-L1 inhibitors through the upregulation of CD8+ T cells, making it a valuable tool for research in colorectal cancer. -
Anti-inflammatory Agent
Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside is a potent anti-inflammatory agent that targets key signaling pathways, including NF-κB, MAPK, and Akt. This compound significantly reduces the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2) in LPS-induced RAW 264.7 macrophages. Additionally, it suppresses the secretion of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, making it valuable for research into inflammation and related disorders. -
COX-1/2 Inhibitor
Cudraflavone B is a prenylated flavonoid that functions as a dual inhibitor of COX-1 and COX-2, demonstrating significant anti-inflammatory and anti-tumor activity. This compound inhibits the translocation of nuclear factor κB (NF-κB) in macrophages, leading to decreased tumor necrosis factor α (TNFα) gene expression and secretion. Additionally, Cudraflavone B induces the mitochondrial apoptotic pathway while activating MAPK signaling pathways, including p38 and ERK, and upregulating SIRT1 expression. These mechanisms contribute to its efficacy in attenuating the growth of human oral squamous cell carcinoma cells, making it a valuable tool for cancer research. -
Anti-inflammatory Agent
rel-Cleroindicin F is an anti-inflammatory agent that targets the NF-κB signaling pathway. It effectively inhibits the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) by downregulating NF-κB and its kinases in LPS-stimulated RAW 264.7 cells. This mechanism contributes to the suppression of inducible nitric oxide synthase expression, leading to decreased NO production. Rel-Cleroindicin F is valuable for research into inflammatory processes and potential therapeutic applications. -
sEH Inhibitor
sEH-IN-21 is a potent inhibitor of soluble epoxide hydrolase (sEH), displaying IC50 values of 0.1 nM for both human and mouse sEH isoforms. This compound effectively inhibits NF-κB signaling pathways and demonstrates significant anti-inflammatory activity by reducing the release of pro-inflammatory cytokines IL-6 and TNF-α. Additionally, sEH-IN-21 helps maintain intestinal barrier integrity, making it a valuable tool for research on inflammatory bowel disease (IBD) and related inflammatory conditions. -
Antitumor Agent
CDN-3 is a cyclic dideoxy nucleotide derivative that functions as an antitumor agent. It stimulates the production of IFN-β and activates the IRF-3 and NF-κB signaling pathways, leading to the induction of type I interferons and pro-inflammatory cytokines such as IL-6 and TNF-α. CDN-3 effectively inhibits the proliferation of cancer cells, making it a valuable tool for investigating mechanisms of colon cancer progression and therapeutic strategies.
